Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

Fig. 1

Patient disposition. *Two patients accompanied with T790M mutation were mistakenly enrolled, one patient was with T790M positive and exon 19 deletion mutation and the other was with T790M positive and L858R mutation. Abbreviations: EGFR, epidermal growth factor receptor; QTcF, QT interval corrected for heart rate using Fridericia’s formula; PD, progressive disease; TEAEs, treatment-emergent adverse events

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us